119.26
-6.04 (-4.82%)
| Penutupan Terdahulu | 125.30 |
| Jumlah Dagangan | 1,366,400 |
| Harga / Pendapatan (P/E Ke hadapan) | 80.00 |
| Harga / Jualan (P/S) | 24.42 |
| Harga / Buku (P/B) | 37.31 |
| Julat 52 Minggu |
| Margin Keuntungan | -265.93% |
| Margin Operasi (TTM) | -247.61% |
| EPS Cair (TTM) | -5.93 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 22.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1,316.96% |
| Nisbah Semasa (MRQ) | 5.86 |
| Aliran Tunai Operasi (OCF TTM) | -761.93 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -480.63 M |
| Pulangan Atas Aset (ROA TTM) | -36.25% |
| Pulangan Atas Ekuiti (ROE TTM) | -890.75% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Insmed Incorporated | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.00 |
|
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 0.75% |
| % Dimiliki oleh Institusi | 110.72% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Baker Bros. Advisors Lp | 30 Jun 2026 | 8,796,111 |
| Darwin Global Management, Ltd. | 30 Jun 2026 | 6,431,163 |
| Orbis Allan Gray Ltd | 30 Jun 2026 | 6,076,487 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BRENNAN DAVID R | - | 128.80 | -25,000 | -3,220,000 |
| Jumlah Keseluruhan Kuantiti Bersih | -25,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -3,220,000 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 128.80 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BRENNAN DAVID R | Pengarah | 09 Sep 2026 | Jual (-) | 25,000 | 128.80 | 3,220,000 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |